InvestorWire NewsRoom


Nemaura Medical Inc. (NASDAQ: NMRD) Reveals Attendance at This Year’s H.C. Wainwright Global Investment Conference
September 27, 2021

Nemaura Medical Inc. (NASDAQ: NMRD) Reveals Attendance at This Year’s H.C. Wainwright Global Investment Conference

  • Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
  • The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021
  • Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs; the company’s flagship product, the sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor designed to help people with diabetes and prediabetes manage their glucose levels.

Nemaura Medical’s management recently revealed their attendance at the 23rd Annual H.C. Wainwright Global Investment Conference, held in an entirely digital forum between September 13-15, 2021 ( Initially founded in 1868, H.C. Wainwright is a U.S.-based investment bank offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions.

The 23rd Annual H.C. Wainwright Global Investment Conference ( featured over 850 corporates in attendance, distributed across six distinctive sector tracks, namely – healthcare & life sciences; metals & mining; cryptocurrency, blockchain, & fintech; cleantech; technology, media & telecommunications; as well as shipping & maritime. In addition, the conference featured some of the industry’s leading keynote speakers, one-on-one investor meetings, and networking opportunities with attendees. H.C. Wainwright’s annual investment conference routinely attracts some of North America’s largest institutional investors, private equity firms, and venture capitalists seeking new investment opportunities.

Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. In the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (

Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable, and flexible method of blood glucose tracking for improved diabetes management. NMRD has positioned itself at the intersection of the global Type 2 diabetes market, which is expected to reach an annual value of nearly $59 billion by 2025. Moreover, the product also allows the company to participate in the $50-plus billion prediabetic market and the wearable health-tech sector for weight loss and wellness applications, which is forecast to hit $60 billion by 2023.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).